Abstract
Background: Napsin A is normally expressed in human lung pneumocytes and is a highly expressed cancer antigen in lung adenocarcinoma. We examined whether T cells specific for Napsin A may play a role in immune checkpoint inhibitor (ICI)-mediated responses. We utilized bulk TCR repertoire data to assess whether the presence of Napsin A-specific clonotypes in the peripheral blood was associated with improved clinical responses to ICI. Methods: Patients with metastatic non-small cell lung cancer (NSCLC) receiving anti-PD-(L)1 (alone or in combination) were enrolled at Fred Hutchinson Cancer Center and Stanford University Medical Center (n=62; histology of adenocarcinoma n=48, squamous n=9, NSCLC/other n=5). Peripheral blood mononuclear cells (PBMC) were collected for genomic DNA isolation pre- and post-treatment (range 3 weeks - 3 months). TCRb was bulk sequenced via the immunoSEQ platform (Adaptive Biotechnologies). Napsin A-specific TCRβ sequences were identified from publicly available data and their frequencies were quantified in each patient sample. We examined whether overall survival (OS) and progression-free survival (PFS) outcomes differed in patients with or without detectable Napsin A-specific TCRs (herein Napsin TCRs). We used Cox proportional hazards regression to assess the association between detectable Napsin TCRs and PFS or OS in univariable and multivariable analyses. Results: Napsin TCRs were detectable in the blood in a large fraction of our cohort (n=25/62 [40%] [pre-treatment; n=21/42 [50%] post-treatment). Patients with detectable Napsin TCRs had a significant improvement in OS compared to patients without these TCRs (median OS 45.4 vs 14.8 months, p=0.0043 pre-treatment; median OS 55.4 vs 18.9 months, p=0.0066 post-treatment). Among 27 HLA-A*02 carriers of 55 HLA-typed patients (49%), patients with detectable pre-treatment Napsin TCRs had a significant improvement in OS (median 60.2 vs 16.5 months, p=0.0054) and PFS (median 21.5 vs. 7.2 months, p=0.031) compared to patients without these TCRs. In univariate and multivariate analysis, the presence of Napsin TCRs pre-treatment was associated with improved OS (p=0.0057, HR 0.40, 95% CI 0.21-0.76 univariate; p=0.033 HR 0.45, 95% CI 0.23-0.91 multivariate). Conclusions: Napsin TCRs are frequently detected in patients with NSCLC and are associated with improved OS in patients with NSCLC receiving ICI.
Competing Interest Statement
No authors report conflicts related to this manuscript. CB reports grants or contracts (to institution) from AstraZeneca, Pfizer, Blueprint, Daiichi, Abbvie, TPTherapeutics, Lilly, Janssen, Nuvalent, Boehringer, BlackDiamond, BristolMyersSquibb, Ellipses; consulting fees from AstraZeneca, Pfizer, Janssen, Boehringer, Daiichi, Genentech, Bristol Myers Squibb, Genentech, Takeda, Regeneron, Janssen, Natera; and participation in advisory board for Daiichi Sankyo. JN reports grants or contracts (to institution) from Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, Janssen, AbbVie, Nuvalent and Novocure; consulting fees from AstraZeneca, Genentech/Roche, Exelixis, Takeda Pharmaceuticals, Eli Lilly and Company, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics, Mirati Therapeutics, Gilead Sciences, AbbVie, Summit Therapeutics, Novartis, Novocure, Janssen Oncology, Anheart Therapeutics, Bristol-Myers Squibb, Daiichi Sankyo/Astra Zeneca and Nuvation Bio; and CME payment/honoraria from CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences CME, Medical Educator Consortium, and HMP Education. RS reports grants or contracts (to institution) from Genentech, BeyondSpring Pharmaceuticals, ISA Pharmaceuticals, Merck, Pfizer, ALX Oncology, AstraZeneca, Daiichi Sankyo/Lilly, Abbvie, Astellas Pharma, Jounce Therapeutics, Alpine Immune Sciences, Monte Rosa Therapeutics; consulting fees from Mirati Therapeutics, Genentech/Roche, Catalyst Pharmaceuticals, Amgen, Fosun Pharma, Boehringer Ingelheim and Daiichi Sankyo. SL reports grants or contracts (to institution) from Iovance, Lyell, Black Diamond, and Pfizer. RM reports consulting fees from Pfizer and honoraria plus travel support from Takeda. CR reports grants or contracts (to institution) from Adagene, BMS, Coherus, Cue Biopharma, Merck, Rgenta, Seagen/Pfizer; advisory board for Eisai, Vaccitech, Coherus, Adaptimmune, Cue Biopharma, and DSMC for Pionyr. HW reports grants or contracts (to institution) from Bayer, AstraZeneca, BristolMyersSquibb, Genentech/Roche, Merck, Helsinn, SeaGen and Xcovery; honoraria from Chugai Pharmaceuticals; participation on advisory board for Mirati, IOBiotech, OncoC4, BeigeneGSK, Merck, Genentech/Roche, BristolMyersSquibb and AstraZeneca; and leadership role in International Association for the Study of Lung Cancer (IASLC) and ECOG-ACRIN. SP reports grants or contracts (to institution) from EpicentRx, Bayer, Boehringer-Ingelheim, Bioalta; advisory boards for Regeneron, Bayer, AstraZeneca, Eli Lily, BMS, Takeda Pharmaceuticals, Summit Therapeutics, Amgen, Sanofi Genzyme, Rayze Biotech, Mirati, Janssen, Jazz Pharma, Genentech, Nanobiotix; and CME payment/honoraria PER, Curio Science LLC, MECC Global Meetings, and CME Solutions. EK reports consulting fees from AstraZeneca and MediaLab; payment/honoraria from MediaLab; and leadership roles with Association for Molecular Pathology, College for American Pathologists, and Washington State Society of Pathologists. VN reports consulting fees to Lyell Immunopharma. DT reports grants or contracts (to institution) from Gilead Sciences, Mythic Therapeutics, Inc, Seagen Inc; royalties from Gilead Sciences via Stanford University; payment or honoraria from the Binaytara Foundation; patent from Gilead Sciences via Stanford University; leadership on Lung Cancer Research Foundation Scientific Advisory Board, and other interests with the Hartwell Innovation Award/ Swim Across America Pilot Award (to institution).
Funding Statement
Federal funding from: NIH U01 CA253 166 (to VN) and NCI P50 CA228944 (to AMH). FHCC SPORE in Lung Cancer Career Enhancement Program Award, Lung Cancer Research Foundation Scientific Grant, NIH/NCI Cancer Center Support Grant P30 CA015704, UW Thoracic/ Head and Neck Medical Oncology Research Pilot Award, Names Family Foundation, Friedman/Rieger Family (to DT), and Joshua Green Foundation salary support (to NM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Fred Hutch Cancer Center (IRB # 9358 and 6663/2242) and Stanford University (IRB #21319) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos